Reconstituted HDL

Drug delivery platform for overcoming biological barriers to cancer therapy

Sangram Limbaji Raut, Linda Mooberry, Nirupama Sabnis, Ashwini Garud, Akpedje Serena Dossou, Andras G. Lacko

Research output: Contribution to journalReview articleResearchpeer-review

3 Citations (Scopus)

Abstract

Drug delivery to malignant tumors is limited by several factors, including off-target toxicities and suboptimal benefits to cancer patient. Major research efforts have been directed toward developing novel technologies involving nanoparticles (NPs) to overcome these challenges. Major obstacles, however, including, opsonization, transport across cancer cell membranes, multidrug-resistant proteins, and endosomal sequestration of the therapeutic agent continue to limit the efficiency of cancer chemotherapy. Lipoprotein-based drug delivery technology, “nature's drug delivery system,” while exhibits highly desirable characteristics, it still needs substantial investment from private/government stakeholders to promote its eventual advance to the bedside. Consequently, this review focuses specifically on the synthetic (reconstituted) high-density lipoprotein rHDL NPs, evaluating their potential to overcome specific biological barriers and the challenges of translation toward clinical utilization and commercialization. This highly robust drug transport system provides site-specific, tumor-selective delivery of anti-cancer agents while reducing harmful off-target effects. Utilizing rHDL NPs for anti-cancer therapeutics and tumor imaging revolutionizes the future strategy for the management of a broad range of cancers and other diseases.

Original languageEnglish
Article number01154
JournalFrontiers in Pharmacology
Volume9
Issue numberOCT
DOIs
StatePublished - 15 Oct 2018

Fingerprint

Pharmaceutical Preparations
Neoplasms
Nanoparticles
Therapeutics
Technology
Reducing Agents
HDL Lipoproteins
Drug Delivery Systems
Lipoproteins
Cell Membrane
Drug Therapy
Research
Proteins

Keywords

  • Biological barriers
  • Cancer therapy and imaging
  • Cholesterol
  • HDL
  • RHDL
  • SR-B1 receptor
  • Tumor targeting

Cite this

Raut, Sangram Limbaji ; Mooberry, Linda ; Sabnis, Nirupama ; Garud, Ashwini ; Dossou, Akpedje Serena ; Lacko, Andras G. / Reconstituted HDL : Drug delivery platform for overcoming biological barriers to cancer therapy. In: Frontiers in Pharmacology. 2018 ; Vol. 9, No. OCT.
@article{a5320b7efcc549b9b15da7fd540d20c2,
title = "Reconstituted HDL: Drug delivery platform for overcoming biological barriers to cancer therapy",
abstract = "Drug delivery to malignant tumors is limited by several factors, including off-target toxicities and suboptimal benefits to cancer patient. Major research efforts have been directed toward developing novel technologies involving nanoparticles (NPs) to overcome these challenges. Major obstacles, however, including, opsonization, transport across cancer cell membranes, multidrug-resistant proteins, and endosomal sequestration of the therapeutic agent continue to limit the efficiency of cancer chemotherapy. Lipoprotein-based drug delivery technology, “nature's drug delivery system,” while exhibits highly desirable characteristics, it still needs substantial investment from private/government stakeholders to promote its eventual advance to the bedside. Consequently, this review focuses specifically on the synthetic (reconstituted) high-density lipoprotein rHDL NPs, evaluating their potential to overcome specific biological barriers and the challenges of translation toward clinical utilization and commercialization. This highly robust drug transport system provides site-specific, tumor-selective delivery of anti-cancer agents while reducing harmful off-target effects. Utilizing rHDL NPs for anti-cancer therapeutics and tumor imaging revolutionizes the future strategy for the management of a broad range of cancers and other diseases.",
keywords = "Biological barriers, Cancer therapy and imaging, Cholesterol, HDL, RHDL, SR-B1 receptor, Tumor targeting",
author = "Raut, {Sangram Limbaji} and Linda Mooberry and Nirupama Sabnis and Ashwini Garud and Dossou, {Akpedje Serena} and Lacko, {Andras G.}",
year = "2018",
month = "10",
day = "15",
doi = "10.3389/fphar.2018.01154",
language = "English",
volume = "9",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S.A.",
number = "OCT",

}

Reconstituted HDL : Drug delivery platform for overcoming biological barriers to cancer therapy. / Raut, Sangram Limbaji; Mooberry, Linda; Sabnis, Nirupama; Garud, Ashwini; Dossou, Akpedje Serena; Lacko, Andras G.

In: Frontiers in Pharmacology, Vol. 9, No. OCT, 01154, 15.10.2018.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Reconstituted HDL

T2 - Drug delivery platform for overcoming biological barriers to cancer therapy

AU - Raut, Sangram Limbaji

AU - Mooberry, Linda

AU - Sabnis, Nirupama

AU - Garud, Ashwini

AU - Dossou, Akpedje Serena

AU - Lacko, Andras G.

PY - 2018/10/15

Y1 - 2018/10/15

N2 - Drug delivery to malignant tumors is limited by several factors, including off-target toxicities and suboptimal benefits to cancer patient. Major research efforts have been directed toward developing novel technologies involving nanoparticles (NPs) to overcome these challenges. Major obstacles, however, including, opsonization, transport across cancer cell membranes, multidrug-resistant proteins, and endosomal sequestration of the therapeutic agent continue to limit the efficiency of cancer chemotherapy. Lipoprotein-based drug delivery technology, “nature's drug delivery system,” while exhibits highly desirable characteristics, it still needs substantial investment from private/government stakeholders to promote its eventual advance to the bedside. Consequently, this review focuses specifically on the synthetic (reconstituted) high-density lipoprotein rHDL NPs, evaluating their potential to overcome specific biological barriers and the challenges of translation toward clinical utilization and commercialization. This highly robust drug transport system provides site-specific, tumor-selective delivery of anti-cancer agents while reducing harmful off-target effects. Utilizing rHDL NPs for anti-cancer therapeutics and tumor imaging revolutionizes the future strategy for the management of a broad range of cancers and other diseases.

AB - Drug delivery to malignant tumors is limited by several factors, including off-target toxicities and suboptimal benefits to cancer patient. Major research efforts have been directed toward developing novel technologies involving nanoparticles (NPs) to overcome these challenges. Major obstacles, however, including, opsonization, transport across cancer cell membranes, multidrug-resistant proteins, and endosomal sequestration of the therapeutic agent continue to limit the efficiency of cancer chemotherapy. Lipoprotein-based drug delivery technology, “nature's drug delivery system,” while exhibits highly desirable characteristics, it still needs substantial investment from private/government stakeholders to promote its eventual advance to the bedside. Consequently, this review focuses specifically on the synthetic (reconstituted) high-density lipoprotein rHDL NPs, evaluating their potential to overcome specific biological barriers and the challenges of translation toward clinical utilization and commercialization. This highly robust drug transport system provides site-specific, tumor-selective delivery of anti-cancer agents while reducing harmful off-target effects. Utilizing rHDL NPs for anti-cancer therapeutics and tumor imaging revolutionizes the future strategy for the management of a broad range of cancers and other diseases.

KW - Biological barriers

KW - Cancer therapy and imaging

KW - Cholesterol

KW - HDL

KW - RHDL

KW - SR-B1 receptor

KW - Tumor targeting

UR - http://www.scopus.com/inward/record.url?scp=85055279498&partnerID=8YFLogxK

U2 - 10.3389/fphar.2018.01154

DO - 10.3389/fphar.2018.01154

M3 - Review article

VL - 9

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - OCT

M1 - 01154

ER -